NCT06769984

A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.

A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Moderate-to-severe Thyroid Eye Disease

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Sinocelltech Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease

Conditions

• TED

Interventions

Type	Name	Description
DRUG	SCTT11	SCTT11 dose 1, dose 2, dose 3, dose 4
DRUG	Placebo	Placebo dose 1, dose 2, dose 3, dose 4

Timeline

• Start date: 2025-02-19
• Primary completion: 2026-06-24
• Completion: 2028-09-19
• First posted: 2025-01-10
• Last updated: 2025-01-10